Novotech Featured Reports
-
COVID-19: Asia Pacific Clinical Trial Landscape
9/29/2022
In December 2019, a novel coronavirus was discovered in China causing severe acute respiratory syndrome-like pneumonia which resulted in a pandemic. Find out more details regarding its spread in this report.
-
Solid Tumors: Asia Pacific Clinical Trial Landscape
9/29/2022
Read more about how the large population and lower volume of studies decreases competing trial risk in this region with a great need for novel drug therapies for solid tumors in Asian patients
-
Psoriasis: Asia Pacific Clinical Trial Landscape
9/29/2022
Psoriasis can have a significant psychological effect on both the patient and their family. Explore the cultural factors, socioeconomic factors, and higher levels of social stigma and prejudice resulting that make this disease more prevalent in Asia.
-
Diffuse Large B-Cell Lymphoma: Asia Pacific Clinical Trial Landscape
9/29/2022
DLBCL is the most prevalent Non-Hodgkin Lymphoma (NHL) which accounts for about 30%-40% of all NHL cases worldwide. Explore its prevalence in the Asia Pacific region in this report.
-
Clostridium Difficile Infection (CDI): Asia Pacific Clinical Trial Landscape
9/29/2022
Clostridium difficile infection is one of the leading causes of morbidity and mortality worldwide. Find out more about this disease in Asia, where a mean overall prevalence of nearly 15.0% was found among hospital patients.
-
Non-Alcoholic Steatohepatitis (NASH): Asia Pacific Clinical Trial Landscape
9/29/2022
Even though NAFLD (non-alcoholic fatty liver disease) is a significant public health burden in the United States and Europe, learn why Asia has a NAFLD burden that is increasing faster than the developed countries of the West.
-
Ulcerative Colitis: The Asia Pacific Clinical Trial Landscape
9/29/2022
Find out how the incidence and prevalence of Ulcerative Colitis in Asia has rapidly increased over the past four decades with an incidence rate of around 6 cases per 100,000 population.